Evinova is shaking up clinical development with strategic collaborations with global pharma leaders Astellas, AstraZeneca, and Bristol Myers Squibb. The partnerships leverage Evinova’s AI-native platform to accelerate clinical trials, streamline operations, and improve patient outcomes.

 

Each company will share operational data with Evinova, feeding the platform’s AI engines to provide benchmarks and actionable insights, aiming to speed up trials while maintaining top-tier patient care.

 

Clinical trials are often slowed by fragmented systems and manual processes. Evinova’s AI-native platform tackles these hurdles with intelligent optimization, faster end-to-end workflows, and multi-agent AI capabilities, enabling partners to innovate with precision and efficiency.

 

Pascal Soriot, CEO of AstraZeneca, said: "This strategic collaboration with Evinova harnesses AI to accelerate clinical development, which we believe will significantly improve productivity gains, deliver faster trials, and enhance patient experience. More broadly, the AI-era will empower us to demonstrate the continued excellence of our science and the benefits it can deliver, fundamentally improving patient care in clinical development and helping us to deliver new medicines.”

 

Tadaaki Taniguchi, Chief R&D Officer at Astellas, added: "At Astellas, we view AI as a practical catalyst for accelerating clinical development, enabling us to bring innovative medicines to patients faster. By partnering with Evinova and leveraging their AI-native Study Designer platform, our teams will be able to design smarter, more patient centered studies, eliminate avoidable rework, and move with greater speed and precision as we pioneer science in breakthrough areas of R&D.”

 

Cristian Massacesi, Chief Medical Officer & Head of Development at Bristol Myers Squibb, said: "Transforming clinical development is not just an opportunity; it is an urgent necessity. For years, developing medicines has taken too long, cost too much money, and mostly resulted in failure. 

 

"Digital tools and AI can help us overcome these limitations and lay the foundation for better health outcomes for countless individuals in the years to come. The decisions we make now will shape the future of medicine, accelerate progress and ensure that the benefits of scientific advancement reach those who need them most.”

 

Cristina Duran, President of Evinova, emphasized: "At Evinova, our mission is to drive meaningful transformation in clinical development for sponsors, sites, and patients. By uniting deep domain expertise with the power of AI, our strategic collaborations with life science leaders are moving the industry from heavy manual, fragmented processes to intelligent, AI-first workflows that deliver measurable benefits at scale.”

 

Evinova’s AI-native platform offers end-to-end clinical development support while keeping full decision control in the hands of users. Its modular, cloud-native architecture enables collaboration, compliance, and integration with proprietary AI models, while opt-in data sharing delivers smarter operational insights.